Sumitomo Dainippon Pharma (4506) Stock Price, Fundamentals & Analysis

What 4506 does

Sumitomo Dainippon Pharma (4506) is a stock listed on the Tokyo Stock Exchange in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. Headquartered in Osaka, Japan, the company manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. Its therapeutic portfolio includes treatments for Parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia, along with atypical antipsychotics, generic products, antiepileptic drugs, carbapenem antibiotics, and veterinary medicines. The company, a subsidiary of Sumitomo Chemical Company, Limited, was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. It has collaboration and license agreements with Otsuka Holdings (4578).

Key numbers explained

• The current price of 1,595 JPY represents the most recent trading value for the stock.
• The trailing P/E ratio of 6 divides the current price by the last twelve months of earnings, showing how much investors pay per unit of past profit.
• The forward P/E ratio of 93.1 uses expected future earnings, which can be much higher or lower than the trailing figure if the market anticipates significant growth or decline.
• The dividend yield of 0% means the company currently pays no dividend, so the exDividendDate of Mar 30, 2023, reflects the last recorded distribution, with 0% of earnings paid out as dividends.
• The beta of 0.48 suggests the stock has historically been less volatile than the overall market.
• The priceToBook ratio of 1.75 compares the market price to the company's book value per share, indicating the market values it at a premium to its net assets.
• The returnOnEquity of 38.5% shows how effectively the company generates profit from shareholders' equity.
• The debt-to-equity ratio of 39.3% indicates the proportion of debt financing relative to equity, with lower values generally suggesting a more conservative capital structure.

What to watch

Investors tracking Sumitomo Dainippon Pharma (4506) often monitor its position among peers like Astellas (4503), Shionogi (4507), and Takeda Pharmaceutical (4502), as well as its inclusion in the Nikkei 225 index. The stock's price has ranged from 1,188 to 3,288 JPY over the last 52 weeks, with a current price change over that period of -3%. Revenue growth of 19.9% year over year and a profitMargin of 23.7% are key indicators of operational performance. The upcoming nextEarningsDate of Oct 30, 2026, will provide a new data point for evaluating the company's trajectory.